{"id":"regadenoson-mri-myocardial-blood-flow","safety":{"commonSideEffects":[{"rate":"26","effect":"Headache"},{"rate":"34","effect":"Flushing"},{"rate":"7","effect":"Chest discomfort"},{"rate":"7","effect":"Dyspnea"},{"rate":"5","effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL3989695","moleculeType":"Small molecule","molecularWeight":"408.38"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Regadenoson binds to adenosine A2A receptors on coronary vascular smooth muscle, causing vasodilation and increasing blood flow to the myocardium. This pharmacologic stress mimics the effect of exercise, allowing visualization of regional myocardial perfusion deficits on MRI without requiring physical exertion. The drug is used as a diagnostic agent to detect coronary artery disease and assess myocardial viability.","oneSentence":"Regadenoson is a selective adenosine A2A receptor agonist that increases coronary blood flow to enable assessment of myocardial perfusion during cardiac MRI imaging.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:04:25.469Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Myocardial perfusion imaging via MRI for detection of coronary artery disease"}]},"trialDetails":[{"nctId":"NCT06854458","phase":"NA","title":"The Multicenter Stress Cardiac Magnetic Resonance Quantitative Perfusion Imaging in the United States Study","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2025-06-27","conditions":"Ischemic Heart Disease (IHD), Cardiac Magnetic Resonance Imaging, Myocardial Blood Flow","enrollment":1000},{"nctId":"NCT06735521","phase":"","title":"Cardiac Magnetic Resonance Stress-perfusion Study in Patinets with Fontan Circulation","status":"RECRUITING","sponsor":"Karolinska Institutet","startDate":"2024-04-15","conditions":"Univentricular Heart, Microvascular Dysfunction, Heart Failure","enrollment":30},{"nctId":"NCT03064295","phase":"","title":"Whole-Heart Myocardial Blood Flow Quantification Using MRI","status":"UNKNOWN","sponsor":"Cedars-Sinai Medical Center","startDate":"2018-03-01","conditions":"Coronary Artery Disease, Coronary Microvascular Disease","enrollment":160},{"nctId":"NCT02589977","phase":"PHASE4","title":"Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF","status":"COMPLETED","sponsor":"Marvin W. Kronenberg, M.D.","startDate":"2015-11","conditions":"Heart Failure, Diastolic, Diastolic Heart Failure, Hypertension","enrollment":55},{"nctId":"NCT02560467","phase":"NA","title":"Perfusion Imaging With Myocardial Contrast Echocardiography in HCM","status":"UNKNOWN","sponsor":"Oregon Health and Science University","startDate":"2015-12-01","conditions":"Hypertrophic Cardiomyopathy","enrollment":10},{"nctId":"NCT01949844","phase":"NA","title":"Artifact-Free High-Resolution Myocardial Perfusion MRI in Subjects With Abnormal Nuclear Myocardial Perfusion Studies","status":"COMPLETED","sponsor":"Daniel S. Berman","startDate":"2014-05-16","conditions":"Coronary Artery Disease, CAD","enrollment":44},{"nctId":"NCT01019486","phase":"PHASE4","title":"Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2009-11","conditions":"Coronary Artery Disease, Type 1 Diabetes Mellitus","enrollment":26},{"nctId":"NCT00859833","phase":"NA","title":"Effects of Body Mass Index on the Hyperemic Response to Regadenoson","status":"COMPLETED","sponsor":"University of Utah","startDate":"2009-02","conditions":"Obesity, Endothelial Dysfunction, Decreased Vascular Flow","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":16,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Regadenoson (Lexiscan)","Prohance (Gadoteridol)"],"phase":"marketed","status":"active","brandName":"Regadenoson MRI myocardial blood flow","genericName":"Regadenoson MRI myocardial blood flow","companyName":"University of Colorado, Denver","companyId":"university-of-colorado-denver","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Regadenoson is a selective adenosine A2A receptor agonist that increases coronary blood flow to enable assessment of myocardial perfusion during cardiac MRI imaging. Used for Myocardial perfusion imaging via MRI for detection of coronary artery disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}